Pharma future looking good?

BusinessWeek, looking at S&P, paints a good picture for the near future of Big Pharma:

Looking ahead to the rest of 2006 and 2007, however, Standard & Poor's believes that the outlook for Big Pharma credit ratings is improving. While the aforementioned concerns still certainly exist, recent key product launches, improving product pipelines, the relative absence of major drug-patent expirations over the intermediate term for several major players, and increased financial flexibility provided by the American Jobs Creation Act lead Standard & Poor's to believe that the negative pressures on ratings have lessened. So the three-year credit-ratings slide for Big Pharma may have subsided. This does not mean that ratings are going to be upgraded anytime soon, so much as that ratings appear to have generally stabilized at their current levels.